ReviewFrontiers in immunology2026
Case report and literature review: neuropsychiatric systemic lupus erythematosus presenting as massive intracerebral hemorrhage.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric systemic lupus erythematosus (NPSLE) encompasses a spectrum of central and peripheral nervous system manifestations. While cerebrovascular events occur in 5%-15% of NPSLE patients, intracerebral hemorrhage (ICH) as the initial presentation of systemic lupus erythematosus (SLE) is exceptionally rare and diagnostically challenging. A 17-year-old female presented with nephrotic syndrome and suddenly developed massive left frontal ICH requiring emergency craniotomy. Vascular malformations were excluded by digital subtraction angiography and intraoperative inspection. Subsequent immunological workup revealed a single positive antinuclear antibody, elevated anti-dsDNA antibodies, positive anti-ribosomal P antibody, positive lupus anticoagulant (LA), and hypocomplementemia, supporting the diagnosis of SLE with active lupus nephritis. She achieved multisystem recovery following aggressive immunosuppressive therapy. In the literature review, 12 clinical studies and 12 case reports were identified. The incidence of ICH was low (0.4%-1.5%), but the associated mortality risk was high (exceeding 20%). Compared with the non-SLE population, patients with SLE face a 2- to 3-fold higher risk of ICH. In case reports, all patients were female, 83.3% were aged ≤ 35 years, and 58.3% presented with ICH at the time of SLE diagnosis. Active lupus nephritis coexisted in 41.7% of cases. Common risk factors associated with the disease include young age, high disease activity, concomitant antiphospholipid syndrome, thrombocytopenia, and the use of antiplatelet agents. NPSLE should be considered in young female patients presenting with spontaneous ICH accompanied by multisystem involvement, particularly when conventional vascular risk factors are absent. The triad of active lupus nephritis, hypocomplementemia, and LA positivity may be associated with a high-risk phenotype for SLE-associated ICH. Timely recognition and appropriate immunomodulation may be important for improving outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.